https://news.medxy.ai/zh/precision-therapy-lqt2/Medxy AIzh2026-09-28T09:57:09-07:00精准治疗长 QT 综合征2型：Lumacaftor纠正转运缺陷并缩短QT间期 https://news.medxy.ai/ja/78879-2/Medxy AIja2026-09-28T09:56:51-07:00ルマカフトール、2型QT延長症候群の精密治療薬として期待 https://news.medxy.ai/vi/precision-medicine-qt-syndrome/Medxy AIvi2026-09-28T09:56:27-07:00Y học chính xác cho hội chứng QT dài тип 2: Lumacaftor khắc phục khiếm khuyết vận chuyển và rút ngắn khoảng QT https://news.medxy.ai/precision-medicine-for-long-qt-syndrome-type-2-lumacaftor-corrects-trafficking-defects-and-shortens-qt-interval/Medxy AIen2026-09-28T09:56:08-07:00Precision Medicine for Long QT Syndrome Type 2: Lumacaftor Corrects Trafficking Defects and Shortens QT Interval https://news.medxy.ai/zh/cancer-gender-differences/Medxy AIzh2026-09-28T09:55:34-07:00癌症发病的性别差异：生活方式与健康因素的综合证据 https://news.medxy.ai/vi/venetoclax-inotuzumab-results/Medxy AIvi2026-09-28T09:55:14-07:00Phối hợp Venetoclax và Inotuzumab Ozogamicin cho thấy kết quả đầy hứa hẹn trong bệnh bạch cầu lympho cấp dòng B tái phát/kháng trị https://news.medxy.ai/vi/gender-cancer-differences/Medxy AIvi2026-09-28T09:54:45-07:00Khác biệt theo giới trong tỷ lệ mắc ung thư: vai trò của lối sống và các tình trạng sức khỏe liên quan https://news.medxy.ai/disparities-in-cancer-incidence-by-sex-and-associated-lifestyle-factors-and-health-conditions-an-integrative-review/Medxy AIen2026-09-28T09:54:22-07:00Disparities in Cancer Incidence by Sex and Associated Lifestyle Factors and Health Conditions: An Integrative Review https://news.medxy.ai/zh/semaglutide-cardiovascular-benefits/Medxy AIzh2026-09-28T08:51:30-07:00司美格鲁肽心血管获益机制再审视：SELECT 试验中介分析解读 https://news.medxy.ai/ja/semaglutide-cardiovascular-protection/Medxy AIja2026-09-28T08:51:13-07:00セマグルチドの心血管保護作用を読み解く：SELECT試験の媒介分析から見えた示唆 https://news.medxy.ai/zh/leukemia-immunotherapy/Medxy AIzh2026-09-28T06:05:15-07:00超越传统靶点：急性髓系白血病精准免疫治疗的新进展 https://news.medxy.ai/ja/precision-immunotherapy/Medxy AIja2026-09-28T06:04:56-07:00急性骨髄性白血病における精密免疫療法：従来標的を超えて https://news.medxy.ai/vi/precision-immunotherapy-in-leukemia/Medxy AIvi2026-09-28T06:04:36-07:00Liệu pháp miễn dịch chính xác trong bạch cầu cấp dòng tủy: Vượt ra ngoài các mục tiêu truyền thống https://news.medxy.ai/precision-immunotherapy-in-acute-myeloid-leukemia-advancing-beyond-traditional-targets/Medxy AIen2026-09-28T06:04:15-07:00Precision Immunotherapy in Acute Myeloid Leukemia: Advancing Beyond Traditional Targets https://news.medxy.ai/zh/mertk-cll-strategy-2/Medxy AIzh2026-09-28T06:03:34-07:00靶向CLL中的MERTK：克服ibrutinib耐药的潜在新策略 https://news.medxy.ai/ja/mertk-targeting-cll/Medxy AIja2026-09-28T06:03:17-07:00CLLにおけるMERTK標的化：Ibrutinib耐性を克服する有望な戦略 https://news.medxy.ai/vi/mertk-cll-strategy/Medxy AIvi2026-09-28T06:02:58-07:00Nhắm đích MERTK trong CLL: Chiến lược đầy hứa hẹn để vượt qua tình trạng kháng ibrutinib https://news.medxy.ai/targeting-mertk-in-cll-a-promising-strategy-for-overcoming-ibrutinib-resistance/Medxy AIen2026-09-28T06:02:37-07:00Targeting MERTK in CLL: A Promising Strategy for Overcoming Ibrutinib Resistance https://news.medxy.ai/zh/adamts13-treatment-benefits/Medxy AIzh2026-09-28T06:02:00-07:00重组ADAMTS13治疗在先天性血栓性血小板减少性紫癜中疗效与安全性优于血浆治疗：3期试验最终结果 https://news.medxy.ai/ja/adamts13-therapy-results/Medxy AIja2026-09-28T06:01:41-07:00先天性TTPに対する組換えADAMTS13療法、血漿療法を上回る有効性と安全性を示す：第3相試験最終結果 https://news.medxy.ai/vi/adamts13-recombinant-benefits/Medxy AIvi2026-09-28T06:01:20-07:00ADAMTS13 tái tổ hợp cho thấy hiệu quả và độ an toàn vượt trội so với liệu pháp huyết tương trong TTP bẩm sinh: Kết quả cuối cùng của thử nghiệm pha 3 https://news.medxy.ai/recombinant-adamts13-therapy-demonstrates-superior-efficacy-and-safety-over-plasma-based-therapy-in-congenital-thrombotic-thrombocytopenic-purpura-final-phase-3-trial-results/Medxy AIen2026-09-28T06:01:01-07:00Recombinant ADAMTS13 Therapy Demonstrates Superior Efficacy and Safety Over Plasma-Based Therapy in Congenital Thrombotic Thrombocytopenic Purpura: Final Phase 3 Trial Results https://news.medxy.ai/zh/srage-ards-lung-recruitment/Medxy AIzh2026-09-28T06:00:24-07:00血浆sRAGE生物标志物助力ARDS个体化肺复张：基于LIVE试验的研究解读 https://news.medxy.ai/ja/plasma-srage-ards/Medxy AIja2026-09-28T06:00:04-07:00血漿sRAGEバイオマーカーがARDSの個別化肺リクルートメント戦略を導く：LIVE試験からの知見 https://news.medxy.ai/vi/srage-plasma-ards/Medxy AIvi2026-09-28T05:59:43-07:00sRAGE huyết tương: chỉ dấu định hướng chiến lược tuyển mộ phổi cá thể hóa trong ARDS từ thử nghiệm LIVE https://news.medxy.ai/plasma-srage-biomarker-guides-personalized-lung-recruitment-strategies-in-ards-insights-from-the-live-trial/Medxy AIen2026-09-28T05:59:22-07:00Plasma sRAGE Biomarker Guides Personalized Lung Recruitment Strategies in ARDS: Insights from the LIVE Trial https://news.medxy.ai/zh/inhaled-treprostinil-ipf-2/Medxy AIzh2026-09-28T05:58:46-07:00吸入性 Treprostinil 在特发性肺纤维化中的应用：TETON-1 与 TETON-2 Ⅲ期联合试验的有力证据 https://news.medxy.ai/ja/treprostinil-ipf-trials/Medxy AIja2026-09-28T05:58:30-07:00特発性肺線維症に対する吸入用Treprostinil：TETON-1・TETON-2第3相試験統合解析が示す確かなエビデンス https://news.medxy.ai/vi/inhaled-treprostinil-ipf/Medxy AIvi2026-09-28T05:58:13-07:00Treprostinil dạng hít trong xơ phổi vô căn: Bằng chứng vững chắc từ phân tích gộp hai thử nghiệm giai đoạn 3 TETON-1 và TETON-2 https://news.medxy.ai/inhaled-treprostinil-in-idiopathic-pulmonary-fibrosis-robust-evidence-from-the-combined-teton-1-and-teton-2-phase-3-trials/Medxy AIen2026-09-28T05:57:56-07:00Inhaled Treprostinil in Idiopathic Pulmonary Fibrosis: Robust Evidence from the Combined TETON-1 and TETON-2 Phase 3 Trials https://news.medxy.ai/zh/hess-screen-test/Medxy AIzh2026-09-28T05:57:15-07:00Hess屏幕试验：区分去代偿性内隐斜与眼睑下垂综合征的关键工具 https://news.medxy.ai/ja/esophoria-eye-syndrome/Medxy AIja2026-09-28T05:57:00-07:00Hess Screen Testで見抜く：decompensated esophoriaとsagging eye syndromeの鑑別 https://news.medxy.ai/vi/hess-screen-test-2/Medxy AIvi2026-09-28T05:56:42-07:00Hess Screen Test: Công cụ then chốt để phân biệt lé ẩn trong trạng thái mất bù với hội chứng mắt sa trễ https://news.medxy.ai/hess-screen-test-a-crucial-tool-to-differentiate-decompensated-esophoria-from-sagging-eye-syndrome/Medxy AIen2026-09-28T05:56:22-07:00Hess Screen Test: A Crucial Tool to Differentiate Decompensated Esophoria from Sagging Eye Syndrome https://news.medxy.ai/ja/botulinum-toxin-throat/Medxy AIja2026-09-28T05:55:46-07:00声門上ボツリヌス毒素注射が喉頭感覚障害の症状を改善 https://news.medxy.ai/vi/botulinum-toxin-treatment/Medxy AIvi2026-09-28T05:55:29-07:00Tiêm Botulinum Toxin vùng trên thanh môn giúp cải thiện triệu chứng rối loạn cảm giác thanh quản https://news.medxy.ai/supraglottic-botulinum-toxin-injection-improves-symptoms-of-laryngeal-sensory-dysfunction/Medxy AIen2026-09-28T05:55:11-07:00Supraglottic Botulinum Toxin Injection Improves Symptoms of Laryngeal Sensory Dysfunction https://news.medxy.ai/zh/risk-benefit-balance-3/Medxy AIzh2026-09-28T05:54:37-07:00风险与获益如何平衡：双侧输卵管卵巢切除术时机对 BRCA1/2 突变携带者卵巢癌风险的影响 https://news.medxy.ai/ja/brca1-2-ovarian-cancer-risk/Medxy AIja2026-09-28T05:54:21-07:00BRCA1/2変異保有者における卵巣癌リスク：両側卵管卵巣摘出術の実施時期はどう影響するか https://news.medxy.ai/vi/ovary-tube-removal-risk/Medxy AIvi2026-09-28T05:54:02-07:00Cắt bỏ hai bên vòi trứng và buồng trứng: thời điểm phẫu thuật ảnh hưởng thế nào đến nguy cơ ung thư buồng trứng ở người mang đột biến BRCA1/BRCA2? https://news.medxy.ai/balancing-risks-the-impact-of-bilateral-salpingo-oophorectomy-timing-on-ovarian-cancer-risk-in-brca1-and-brca2-mutation-carriers/Medxy AIen2026-09-28T05:53:45-07:00Balancing Risks: The Impact of Bilateral Salpingo-Oophorectomy Timing on Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers https://news.medxy.ai/zh/tia-dementia-risk/Medxy AIzh2026-09-28T05:53:11-07:00TIA后的长期痴呆风险：一项人群研究揭示持续性的认知威胁 https://news.medxy.ai/ja/tia-dementia-risk-2/Medxy AIja2026-09-28T05:52:52-07:00TIA後の認知症リスクは長期に持続するのか：人口ベース研究が示した持続的な認知的脅威 https://news.medxy.ai/vi/long-term-dementia-risk-after-tia/Medxy AIvi2026-09-28T05:52:33-07:00Nguy cơ sa sút trí tuệ dài hạn sau TIA: Nghiên cứu dựa trên quần thể cho thấy mối đe dọa nhận thức kéo dài https://news.medxy.ai/long-term-dementia-risk-after-tia-a-population-based-study-reveals-sustained-cognitive-threat/Medxy AIen2026-09-28T05:52:13-07:00Long-Term Dementia Risk After TIA: A Population-Based Study Reveals Sustained Cognitive Threat https://news.medxy.ai/vi/semaglutide-heart-benefits/Medxy AIvi2026-09-28T05:50:52-07:00Semaglutide và lợi ích tim mạch: Giải mã phân tích trung gian từ thử nghiệm SELECT https://news.medxy.ai/unraveling-the-cardiovascular-benefits-of-semaglutide-insights-from-the-select-trial-mediation-analysis/Medxy AIen2026-09-28T05:50:34-07:00Unraveling the Cardiovascular Benefits of Semaglutide: Insights from the SELECT Trial Mediation Analysis https://news.medxy.ai/zh/78742-2/Medxy AIzh2026-09-28T05:35:30-07:00EYS相关视网膜变性：遗传多样性、临床表现及疾病进展 https://news.medxy.ai/ja/eys-retinal-degeneration-korea/Medxy AIja2026-09-28T05:35:12-07:00韓国におけるEYS関連網膜変性：遺伝的多様性、臨床像、疾患進行の新知見 https://news.medxy.ai/vi/eys-retinopathy-korea/Medxy AIvi2026-09-28T05:34:50-07:00Thoái hóa võng mạc liên quan đến EYS ở Hàn Quốc: biến thiên di truyền, đặc điểm lâm sàng và tiến triển bệnh https://news.medxy.ai/eys-associated-retinal-degeneration-in-south-korea-insights-into-genetic-variability-clinical-features-and-disease-progression/Medxy AIen2026-09-28T05:34:31-07:00EYS-Associated Retinal Degeneration in South Korea: Insights into Genetic Variability, Clinical Features, and Disease Progression https://news.medxy.ai/zh/parathyroid-identification/Medxy AIzh2026-09-28T05:33:54-07:00甲状腺切除术中甲状旁腺肉眼识别的临床价值：基于决策曲线分析的研究洞见 https://news.medxy.ai/ja/78736-2/Medxy AIja2026-09-28T05:33:35-07:00甲状腺切除術中における副甲状腺の肉眼的同定 https://news.medxy.ai/vi/parathyroid-identification-2/Medxy AIvi2026-09-28T05:33:15-07:00Đánh giá nhận diện tuyến cận giáp bằng mắt thường trong phẫu thuật cắt tuyến giáp: góc nhìn từ phân tích đường cong quyết định https://news.medxy.ai/evaluating-visual-parathyroid-identification-during-thyroidectomy-insights-from-decision-curve-analysis/Medxy AIen2026-09-28T05:32:56-07:00Evaluating Visual Parathyroid Identification During Thyroidectomy: Insights from Decision Curve Analysis https://news.medxy.ai/zh/parathyroidectomy-bisphosphonates-bone-density/Medxy AIzh2026-09-28T05:32:18-07:00甲状旁腺切除术与双膦酸盐治疗对骨密度影响的评估：来自多机构研究的启示 https://news.medxy.ai/ja/parathyroid-surgery-bisphosphonate/Medxy AIja2026-09-28T05:31:58-07:00副甲状腺摘出術とビスホスホネート療法は骨密度をどこまで改善するか：多施設研究からの知見 https://news.medxy.ai/vi/parathyroid-bisphosphonates-bone-density/Medxy AIvi2026-09-28T05:31:37-07:00Cắt tuyến cận giáp và bisphosphonates ảnh hưởng thế nào đến mật độ xương? Kết quả từ một nghiên cứu đa cơ sở https://news.medxy.ai/evaluating-the-impact-of-parathyroidectomy-and-bisphosphonate-therapy-on-bone-mineral-density-insights-from-a-multi-institutional-study/Medxy AIen2026-09-28T05:31:17-07:00Evaluating the Impact of Parathyroidectomy and Bisphosphonate Therapy on Bone Mineral Density: Insights from a Multi-Institutional Study https://news.medxy.ai/zh/tubo-ovarian-abscess/Medxy AIzh2026-09-28T05:30:39-07:00输卵管卵巢脓肿治疗新证据：经阴道引流与腹腔镜的多中心随机试验对比 https://news.medxy.ai/ja/tubo-ovarian-abscess-2/Medxy AIja2026-09-28T05:30:21-07:00卵管卵巣膿瘍に対する経腟ドレナージと腹腔鏡手術の比較：多施設ランダム化試験からの知見 https://news.medxy.ai/vi/vaginal-drainage-vs-laparoscopy/Medxy AIvi2026-09-28T05:30:03-07:00Dẫn lưu qua đường âm đạo hay nội soi ổ bụng trong áp-xe vòi trứng-buồng trứng? Kết quả từ một thử nghiệm ngẫu nhiên đa trung tâm https://news.medxy.ai/assessing-transvaginal-drainage-versus-laparoscopy-for-tubo-ovarian-abscess-insights-from-a-multicenter-randomized-trial/Medxy AIen2026-09-28T05:29:46-07:00Assessing Transvaginal Drainage Versus Laparoscopy for Tubo-Ovarian Abscess: Insights from a Multicenter Randomized Trial https://news.medxy.ai/zh/advanced-ovarian-cancer-trial/Medxy AIzh2026-09-28T05:29:11-07:00晚期上皮性卵巢癌中卡铂、紫杉醇与帕博利珠单抗联合HIPEC及奥拉帕利维持治疗的创新性Ⅱ期试验 https://news.medxy.ai/ja/ovarian-cancer-trial/Medxy AIja2026-09-28T05:28:52-07:00進行上皮性卵巣癌に対する carboplatin/paclitaxel と pembrolizumab、HIPEC および olaparib 維持療法を組み合わせた革新的第II相試験 https://news.medxy.ai/vi/advanced-phase-ii-carboplatin-paclitaxel-pembrolizumab-ovarian-cancer/Medxy AIvi2026-09-28T05:28:33-07:00Thử nghiệm pha II tiên tiến về carboplatin, paclitaxel và pembrolizumab kết hợp HIPEC cùng duy trì olaparib trong ung thư biểu mô buồng trứng tiến triển https://news.medxy.ai/innovative-phase-ii-trial-of-carboplatin-paclitaxel-and-pembrolizumab-with-hipec-and-olaparib-maintenance-in-advanced-epithelial-ovarian-cancer/Medxy AIen2026-09-28T05:28:14-07:00Innovative Phase II Trial of Carboplatin, Paclitaxel, and Pembrolizumab with HIPEC and Olaparib Maintenance in Advanced Epithelial Ovarian Cancer https://news.medxy.ai/zh/predicting-first-nations-births/Medxy AIzh2026-09-28T05:27:37-07:00预测 First Nations 妇女足月分娩：来自昆士兰队列研究的启示 https://news.medxy.ai/ja/first-nations-delivery/Medxy AIja2026-09-28T05:27:21-07:00First Nations女性の正期産を予測する：クイーンズランド・コホート研究からの知見 https://news.medxy.ai/vi/full-term-birth-forecast/Medxy AIvi2026-09-28T05:27:02-07:00Dự báo sinh đủ tháng ở phụ nữ First Nations: Phát hiện từ một nghiên cứu đoàn hệ tại Queensland https://news.medxy.ai/predicting-term-birth-among-first-nations-women-insights-from-a-queensland-cohort-study/Medxy AIen2026-09-28T05:26:45-07:00Predicting Term Birth Among First Nations Women: Insights from a Queensland Cohort Study https://news.medxy.ai/zh/78712-2/Medxy AIzh2026-09-28T05:26:10-07:00丁酰胆碱酯酶：肝纤维化潜在能靶点 https://news.medxy.ai/ja/78711-2/Medxy AIja2026-09-28T05:25:52-07:00肝線維化におけるブチリルコリンエステラーゼの役割：肝疾患における新たなコリン作動性標的 https://news.medxy.ai/vi/butyrylcholinesterase-liver-fibrosis/Medxy AIvi2026-09-28T05:25:33-07:00Vai trò của Butyrylcholinesterase trong xơ hóa gan: một mục tiêu cholinergic mới trong bệnh gan https://news.medxy.ai/unveiling-the-role-of-butyrylcholinesterase-in-hepatic-fibrosis-a-novel-cholinergic-target-in-liver-disease/Medxy AIen2026-09-28T05:25:12-07:00Unveiling the Role of Butyrylcholinesterase in Hepatic Fibrosis: A Novel Cholinergic Target in Liver Disease https://news.medxy.ai/zh/young-adult-stroke-rise/Medxy AIzh2026-09-28T05:24:36-07:00年轻成人卒中发病上升：来自人群研究的危险因素演变与死亡趋势 https://news.medxy.ai/ja/stroke-increase-young-adults/Medxy AIja2026-09-28T05:24:20-07:00若年成人で脳卒中が増加：人口ベース研究が示す危険因子の変化と死亡率の推移 https://news.medxy.ai/vi/stroke-increase-young/Medxy AIvi2026-09-28T05:23:58-07:00Đột quỵ gia tăng ở người trẻ: thay đổi hồ sơ nguy cơ và xu hướng tử vong từ một nghiên cứu dựa trên quần thể https://news.medxy.ai/rising-stroke-incidence-in-young-adults-evolving-risk-profiles-and-mortality-trends-from-a-population-based-study/Medxy AIen2026-09-28T05:23:37-07:00Rising Stroke Incidence in Young Adults: Evolving Risk Profiles and Mortality Trends from a Population-Based Study https://news.medxy.ai/zh/multidimensional-decline/Medxy AIzh2026-09-28T05:23:03-07:00多维功能衰退早于心血管事件：ASPREE 研究新启示 https://news.medxy.ai/ja/functional-decline-cardiovascular-events/Medxy AIja2026-09-28T05:22:45-07:00機能低下は心血管イベントに先行する：ASPREE研究が示す新知見 https://news.medxy.ai/vi/multidimensional-function-decline/Medxy AIvi2026-09-28T05:22:26-07:00Suy giảm chức năng đa chiều báo trước biến cố tim mạch: Góc nhìn từ nghiên cứu ASPREE https://news.medxy.ai/multidimensional-functional-decline-precedes-cardiovascular-events-insights-from-the-aspree-study/Medxy AIen2026-09-28T05:22:08-07:00Multidimensional Functional Decline Precedes Cardiovascular Events: Insights from the ASPREE Study https://news.medxy.ai/zh/af-density-stroke-risk/Medxy AIzh2026-09-28T05:21:32-07:00心房颤动密度：一种提升缺血性卒中风险预测的新型生物标志物 https://news.medxy.ai/ja/afib-density-stroke-risk/Medxy AIja2026-09-28T05:21:12-07:00心房細動密度：虚血性脳卒中リスク予測を高める新たなバイオマーカー https://news.medxy.ai/vi/afib-density-biomarker/Medxy AIvi2026-09-28T05:20:49-07:00Mật độ rung nhĩ: biomarker mới giúp dự báo chính xác hơn nguy cơ đột quỵ thiếu máu cục bộ https://news.medxy.ai/atrial-fibrillation-density-a-novel-biomarker-enhancing-ischaemic-stroke-risk-prediction/Medxy AIen2026-09-28T05:20:29-07:00Atrial Fibrillation Density: A Novel Biomarker Enhancing Ischaemic Stroke Risk Prediction https://news.medxy.ai/zh/venous-integrity/Medxy AIzh2026-09-28T02:09:59-07:00静脉完整性：预测乳头保留乳腺切除术后乳头-乳晕复合体坏死的关键指标 https://news.medxy.ai/ja/venous-integrity-nac-necrosis/Medxy AIja2026-09-28T02:09:35-07:00乳頭温存乳房切除術後NAC壊死の鍵となる予測因子としての静脈の完全性 https://news.medxy.ai/vi/vein-integrity-predictor/Medxy AIvi2026-09-28T02:09:13-07:00Tính toàn vẹn tĩnh mạch: yếu tố dự báo then chốt của hoại tử phức hợp quầng-vú sau phẫu thuật cắt tuyến vú bảo tồn núm vú https://news.medxy.ai/venous-integrity-as-a-key-predictor-of-nipple-areolar-complex-necrosis-following-nipple-sparing-mastectomy/Medxy AIen2026-09-28T02:08:53-07:00Venous Integrity as a Key Predictor of Nipple-Areolar Complex Necrosis Following Nipple-Sparing Mastectomy